Soluble Fas mRNA is dominantly expressed in cases with silicosis

Immunology

Volumn 94, Issue 2, 1998, Pages 258-262

  Otsuki, T ^a   Sakaguchi, H ^a   Tomokuni, A ^a   Aikoh, T ^a   Matsuki, T ^a   Kawakami, Y ^a   Kusaka, M ^b   Ueki, H ^a   Kita, S ^a   Ueki, A ^a  

^a KAWASAKI MEDICAL SCHOOL   (Japan)

^b Kusaka Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN; MESSENGER RNA;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNITY; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SILICOSIS;

ADULT; AGED; ANTIGENS, CD95; FAS LIGAND PROTEIN; FEMALE; GENE EXPRESSION; HUMANS; LIGANDS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SILICOSIS; SOLUBILITY;

EID: 7144223430     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.1998.00509.x     Document Type: Article

References (35)

1. BRAMWELL, B. (1914) Diffuse scleroderma: its frequency; its occurrence in stonemasons; its treatment by fibrinolysis-elevations of temperature due to fibrinolysis injections. Ed Med J 12, 387.
2. CAPLAN A. (1953) Certain unusual radiological appearances in the chest of coal-miners suffering from rheumatoid arthritis. Thorax 8, 29.
3. ERASMUS L.D. (1958) Scleroderma in gold-miners on the Witwatersrand with particular reference to pulmonary manifestations. S Afr J Lab Clin Med 3, 209.
4. RODNAN G.P., BENEDEK T.G., MEDSGER T.A. & CAMMARATA R.J. (1967) The association of progressive systemic sclerosis (scleroderma) with coal miners' pneumoconiosis and other forms of silicosis. Ann Intern Med 66, 323.
5. HASLAM L.P. (1994) Basic immunology and immunopathology. In: Occupational Lung Disorders (ed W. R. Parkers), 3rd edn, p. 50. Butterworth Heinemann, London.
6. UEKI A., KINUGAWA K., HYODOH F., KAWAKAMI Y., SAKAGUCHI H. & MIYAHARA Y. (1996) The role of silica compounds in the autoimmune diseases accompanied by silicosis. Arch Complex Environ Studies 8, 53.
7. + T cells by chrysotile asbestos in vitro. Cancer Lett 66, 99.
8. + lymphocytes can be stimulated by crocidolite, anthophyllite and amosite asbestos in vitro. Int J Oncol 2, 209.
9. UEKI A., YAMAGUCHI M., UEKI H. et al. (1994) Polyclonal human T-cell activation by silicate in vitro. Immunology 82, 332.
10. UEKI A., NAKASHIMA M., KISHIMOTO T., NAKAMURA J., KINUGAWA K. & SAKAGUCHI H. (1996) Analysis of the expression of TCR Vβ repertoires in patients with silicosis. J Occup Health 38, 67.
11. ITOH N., YONEHARA S., ISHII A. et al. (1991) The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66, 233.
12. ITOH N. & NAGATA S. (1993) A novel protein domain required for apoptosis. Mutational analysis of human Fas antigen. J Biol Chem 268, 10932.
13. NAGATA S. & GOLDSTEIN P. (1995) The Fas death factor. Science 267, 1449.
14. NAGATA S. (1997) Apoptosis by death factor. Cell 88, 355.
15. CASCINO I., FIUCCI G., PAPOFF G. & RUBERTI G. (1995) Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 154, 2706.
16. LIU C., CHENG J. & MOUNTZ J.D. (1995) Differential expression of human Fas mRNA species upon peripheral blood mononuclear cell activation. Biochem J 310, 957.
17. PAPOFF G., CASCINO I., ERAMO A., STARACE G., LYNCH D.H. & RUBERTI G. (1996) An N-terminal domain shared by Fas/Apo-1 (CD95) soluble variants prevents cell death in vitro. J Immunol 156, 4622.
18. RUBERTI G., CASCINO I., PAPOFF G. & ERAMO A. (1996) Fas splicing variants and their effect on apoptosis. Adv Exp Med Biol 406, 125.
19. CHENG J., ZHOU T., LIU C. et al. (1994) Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263, 1759.
20. KNIPPING E., KRAMMERE P.H., ONEL K.B., LEHMAN T.J., MYSLER E. & ELKON K.B. (1995) Levels of soluble Fas/Apo-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis. Arthritis Rheum 38, 1735.
21. JODO S., KOBAYASHI S., KOYANAGI N. et al. (1997) Serum levels of soluble Fas/Apo-1 (CD95) and its molecular structure in patients with systemic erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 107, 89.
22. OKUBO M., ISHIDA H. & KASUKAWA R. (1996) Elevated levels of soluble Fas in systemic lupus erythematosus. Arthritis Rheum 39, 1612.
23. MOUNZT J.D., ZHOU T. & CHENG J. (1996) Use of sensitive assays to detect soluble Fas in patients with systemic lupus erythematosus. Arthritis Rheum 39, 1611.
24. KNIPPING E.K., DEBATIN M., STRICKER K., HEILING B., EDER A. & KRAMMER P.H. (1995) Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood 85, 1562.
25. THOMPSON C.B. (1995) Apoptosis in the pathogenesis and treatment of disease. Science 267, 1456.
26. NAGATA S. & SUDA T. (1995) Fas and Fas ligand: Ipr and gld mutations. Immunol Today 16, 39.
27. KOTZIN B.L. (1996) Systemic lupus erythematosus. Cell 85, 303.
28. MOUNZT J.D., ZHOU T., SU X., WU J. & CHENG J. (1996) The role of programmed cell death as an emerging new concept for the pathogenesis of autoimmune diseases. Clin Immunol Immunopathol 80(3 Pt 2), S2.
29. TOMOKUNI A., AIKOH T., MATSUKI T. et al. (1997) Elevated soluble Fas APO-1 (CD95) levels in silicosis patients without clinical symptoms of autoimmune diseases or malignant tumors. Clin Exp Immunol 110, 303.
30. WATANABE-FUKUNAGA R., BRANNAN C.I., COPELAND N.G., JENKINS N.A. & NAGATA S. (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314.
31. TAKAHASHI T., TANAKA M., BRANNAN C.I. et al. (1994) Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76, 969.
32. RIEUZ-LAUCAT F., LE DEIST F., HIVROZ C. et al. (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268, 1347.
33. FISHER G.H., ROSENBERG F.J., STRAUS S.E. et al. (1995) Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 81, 935.
34. DRAPPA J., VAISHNEN A.K., SULLIVAN K.E., CHU J.-L. & ELKON K. (1996) Fas gene mutations in the Canale Smith syndrome, an inherited lymphoproliferalive disorder associated with autoimmunity. N Engl J Med 335, 1643.
35. WU J., WILSON J., HE J., XIANG L., SCHUR P.H. & MOUNTZ J.D. (1996) Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 98, 1107.